Global Giant Cell Arteritis Therapeutics Market-Industry Analysis, Growth, Segmentation and Forecast-2020-2026

Global Giant Cell Arteritis Therapeutics Market is expected to reach US$ 1.3 Bn. at a CAGR of 6 during the forecast period 2026.

Global Giant Cell Arteritis Therapeutics Market Introduction and Overview:

Giant cell arteritis (GCA) is a granulomatous medium and large-vessel vasculitis. It is the most common form of systemic vasculitis, with an incidence of between 15 and 25 cases per 100,000 persons over 50 years of age. The incidence of GCA increases with age, almost exclusively affecting people 50 years of age or older. Women account for 65–75% of patients; the lifetime risk of GCA in women is 1% compared with 0.5% in men. It mainly affects Caucasians and has a higher incidence in Scandinavian countries and in populations of northern European descent. It is rare in Asian and Black Caribbean/African populations. Hence, the European Market for GCA is expected to grow at a faster pace. The recent introduction of targeted therapies into the treatment landscape for GCA may shed light on the participation of specific pathways in the pathogenesis of the disease. This key factor is expected to drive the market at a higher rate. The treatment of GCA rests on daily glucocorticoid administration, which should be started on an emergency basis in patients with incipient visual impairments. The U.S. Food and Drug Administration has approved the use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the first FDA-approved therapy, specific to this type of vasculitis. Roche co-developed tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for the treatment of moderate-to-severe Giant Cell arthritis. This is boosting the GCA market globally.

Global Giant Cell Arteritis Therapeutics Market Dynamics:

The rise in awareness and technological advancements in health care are encouraging people to opt for advanced and modern treatment procedures for treating giant cell arteritis. This is projected to fuel the growth of the global giant cell arteritis treatment market.

Global Giant Cell Arteritis Therapeutics Market Segment Analysis:

The therapeutics segment dominated the Global GCA market with a revenue value of $xx Mn in 2019 and is expected to continue the same. The segment is further divided into- Prednisone, Methotrexate, Tocilizumab, Aspirin and others. Tocilizumab and other therapeutics dominated the GCA market with their efficiencies in treatment. Tocilizumab (TOC) is a humanized monoclonal antibody that blocks IL-6 signaling by binding to the alpha chain of the human IL-6 receptor. Genentech got FDA approval for a single-dose autoinjector filled with tocilizumab (Actemra) for patients with giant cell arteritis (GCA). Global Giant Cell Arteritis Therapeutics Market To Know About The Research Methodology :- Request Free Sample Report The device, ACTPen 162 mg/0.9 mL, became available in January 2019. The entry of this device raised the revenue for GCA market. Methotrexate is a folic acid antagonist that is used widely, at higher doses to treat malignnt conditions and at low doses as a disease‐modifying anti‐rheumatic drug (DMARD). By mechanism of action, corticosteroid and immunosuppressants segment gear up the market.

Global Giant Cell Arteritis Therapeutics Market Regional Insights:

Global Giant Cell Arteritis Therapeutics Market 1 North America accounted for the largest market share of xx% in 2020 and is expected to grow a CAGR of xx% in the forecast period. Growth in insurance coverage, presence of centers and institutes engaged in R&D and government funding are surging the North American market. Well-established healthcare infrastructure, ease of availability, and increasing immunization programs are also key drivers affecting the market growth. Investments by key players in this field have boosted the market growth. Europe is also expected to drive the market and the factors responsible for growth are the growing acceptance of emerging advanced technologies, rising incidence of GCA and tetanus. Global Giant Cell Arteritis Therapeutics Market 2 The Asia Pacific is also expected to witness significant growth during the forecast period due to rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected to drive the market demand. Awareness programs by governments are also driving the market in the region.

Scope of Giant Cell Arteritis Therapeutics Market: Inquiry before Buying

Global Giant Cell Arteritis Therapeutics Market3

Giant Cell Arteritis Treatment Market, By Region

• North America • Europe • South America • MEA • Asia Pacific

Key players operating in the Global Giant Cell Arteritis Treatment market

• Sanofi • Kiniksa Pharmaceuticals, Ltd. • Regeneron • GlaxoSmithKline plc • F. Hoffmann-La Roche Ltd. • Novartis AG • AbbVie, Inc. • Bristol-Myers Squibb Company • Abbott • Johnson & Johnson Services, Inc. • Johns Hopkins Hospital • Fortis Healthcare • American College of Rheumatology • Duke University Health System • Lahey Clinic Foundation The report also helps in understanding Global Giant Cell Arteritis Therapeutics market dynamics, structure by analysing the market segments and project the Global Giant Cell Arteritis Therapeutics market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Giant Cell Arteritis Therapeutics market make the report investor’s guide.
Global Giant Cell Arteritis Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: GIANT CELL ARTERITIS THERAPEUTICS Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global GIANT CELL ARTERITIS THERAPEUTICS Market Analysis and Forecast 6.1. GIANT CELL ARTERITIS THERAPEUTICS Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global GIANT CELL ARTERITIS THERAPEUTICS Market Analysis and Forecast, By Therapeutics 7.1. Introduction and Definition 7.2. Key Findings 7.3. GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Therapeutics 7.4. GIANT CELL ARTERITIS THERAPEUTICS Market Size (US$ Mn) Forecast, By Therapeutics 7.5. GIANT CELL ARTERITIS THERAPEUTICS Market Analysis, By Therapeutics 7.6. GIANT CELL ARTERITIS THERAPEUTICS Market Attractiveness Analysis, By Therapeutics 8. Global GIANT CELL ARTERITIS THERAPEUTICS Market Analysis and Forecast, By Route of Administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Route of Administration 8.4. GIANT CELL ARTERITIS THERAPEUTICS Market Size (US$ Mn) Forecast, By Route of Administration 8.5. GIANT CELL ARTERITIS THERAPEUTICS Market Analysis, By Route of Administration 8.6. GIANT CELL ARTERITIS THERAPEUTICS Market Attractiveness Analysis, By Route of Administration 9. Global GIANT CELL ARTERITIS THERAPEUTICS Market Analysis and Forecast By Mechanism of Action 9.1. Introduction and Definition 9.2. Key Findings 9.3. GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Mechanism of Action 9.4. GIANT CELL ARTERITIS THERAPEUTICS Market Size (US$ Mn) Forecast, By Mechanism of Action 9.5. GIANT CELL ARTERITIS THERAPEUTICS Market Analysis, By Mechanism of Action 9.6. GIANT CELL ARTERITIS THERAPEUTICS Market Attractiveness Analysis, By Mechanism of Action 10. Global GIANT CELL ARTERITIS THERAPEUTICS Market Analysis, By Region 10.1. GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Region 10.2. GIANT CELL ARTERITIS THERAPEUTICS Market Size (US$ Mn) Forecast, By Region 10.3. GIANT CELL ARTERITIS THERAPEUTICS Market Attractiveness Analysis, By Region 11. North America GIANT CELL ARTERITIS THERAPEUTICS Market Analysis 11.1. Key Findings 11.2. North America GIANT CELL ARTERITIS THERAPEUTICS Market Overview 11.3. North America GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Therapeutics 11.4. North America GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 11.4.1. Prednisone 11.4.2. Methotrexate 11.4.3. Tocilizumab 11.4.4. Aspirin 11.5. North America GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Route of Administration 11.6. North America GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 11.6.1. Oral 11.6.2. Intravenous 11.6.3. Subcutaneous 11.6.4. Others 11.7. North America GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Mechanism of Action 11.8. North America GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 11.8.1. Corticosteroids 11.8.2. Immunosuppressive Agents 11.8.3. Anticoagulants 11.8.4. Others 11.9. North America GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Country 11.10. North America GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Country 11.10.1. U.S. 11.10.2. Canada 11.10.3. Mexico 11.11. North America GIANT CELL ARTERITIS THERAPEUTICS Market Analysis, By Country 11.12. U.S. GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 11.12.1. Prednisone 11.12.2. Methotrexate 11.12.3. Tocilizumab 11.12.4. Aspirin 11.13. U.S. GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 11.13.1. Oral 11.13.2. Intravenous 11.13.3. Subcutaneous 11.13.4. Others 11.14. U.S. GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 11.14.1. Corticosteroids 11.14.2. Immunosuppressive Agents 11.14.3. Anticoagulants 11.14.4. Others 11.15. Canada GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 11.15.1. Prednisone 11.15.2. Methotrexate 11.15.3. Tocilizumab 11.15.4. Aspirin 11.16. Canada GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 11.16.1. Oral 11.16.2. Intravenous 11.16.3. Subcutaneous 11.16.4. Others 11.17. Canada GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 11.17.1. Corticosteroids 11.17.2. Immunosuppressive Agents 11.17.3. Anticoagulants 11.17.4. Others 11.18. Mexico GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 11.18.1. Prednisone 11.18.2. Methotrexate 11.18.3. Tocilizumab 11.18.4. Aspirin 11.19. Mexico GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 11.19.1. Oral 11.19.2. Intravenous 11.19.3. Subcutaneous 11.19.4. Others 11.20. Mexico GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 11.20.1. Corticosteroids 11.20.2. Immunosuppressive Agents 11.20.3. Anticoagulants 11.20.4. Others 11.21. North America GIANT CELL ARTERITIS THERAPEUTICS Market Attractiveness Analysis 11.21.1. By Therapeutics 11.21.2. By Route of Administration 11.21.3. By Mechanism of Action 11.22. PEST Analysis 11.23. Key Trends 11.24. Key Developments 12. Europe GIANT CELL ARTERITIS THERAPEUTICS Market Analysis 12.1. Key Findings 12.2. Europe GIANT CELL ARTERITIS THERAPEUTICS Market Overview 12.3. Europe GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Therapeutics 12.4. Europe GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 12.4.1. Prednisone 12.4.2. Methotrexate 12.4.3. Tocilizumab 12.4.4. Aspirin 12.5. Europe GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Route of Administration 12.6. Europe GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 12.6.1. Oral 12.6.2. Intravenous 12.6.3. Subcutaneous 12.6.4. Others 12.7. Europe GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Mechanism of Action 12.8. Europe GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 12.8.1. Corticosteroids 12.8.2. Immunosuppressive Agents 12.8.3. Anticoagulants 12.8.4. Others 12.9. Europe GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Country 12.10. Europe GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Sweden 12.10.7. CIS countries 12.10.8. Rest of Europe 12.11. Germany GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 12.11.1. Prednisone 12.11.2. Methotrexate 12.11.3. Tocilizumab 12.11.4. Aspirin 12.12. Germany GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 12.12.1. Oral 12.12.2. Intravenous 12.12.3. Subcutaneous 12.12.4. Others 12.13. Germany GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 12.13.1. Corticosteroids 12.13.2. Immunosuppressive Agents 12.13.3. Anticoagulants 12.13.4. Others 12.14. U.K. GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 12.14.1. Prednisone 12.14.2. Methotrexate 12.14.3. Tocilizumab 12.14.4. Aspirin 12.15. U.K. GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 12.15.1. Oral 12.15.2. Intravenous 12.15.3. Subcutaneous 12.15.4. Others 12.16. U.K. GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 12.16.1. Corticosteroids 12.16.2. Immunosuppressive Agents 12.16.3. Anticoagulants 12.16.4. Others 12.17. France GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 12.17.1. Prednisone 12.17.2. Methotrexate 12.17.3. Tocilizumab 12.17.4. Aspirin 12.18. France GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 12.18.1. Oral 12.18.2. Intravenous 12.18.3. Subcutaneous 12.18.4. Others 12.19. France GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 12.19.1. Corticosteroids 12.19.2. Immunosuppressive Agents 12.19.3. Anticoagulants 12.19.4. Others 12.20. Italy GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 12.20.1. Prednisone 12.20.2. Methotrexate 12.20.3. Tocilizumab 12.20.4. Aspirin 12.21. Italy GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 12.21.1. Oral 12.21.2. Intravenous 12.21.3. Subcutaneous 12.21.4. Others 12.22. Italy GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 12.22.1. Corticosteroids 12.22.2. Immunosuppressive Agents 12.22.3. Anticoagulants 12.22.4. Others 12.23. Spain GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 12.23.1. Prednisone 12.23.2. Methotrexate 12.23.3. Tocilizumab 12.23.4. Aspirin 12.24. Spain GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 12.24.1. Oral 12.24.2. Intravenous 12.24.3. Subcutaneous 12.24.4. Others 12.25. Spain GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 12.25.1. Corticosteroids 12.25.2. Immunosuppressive Agents 12.25.3. Anticoagulants 12.25.4. Others 12.26. Sweden GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 12.26.1. Prednisone 12.26.2. Methotrexate 12.26.3. Tocilizumab 12.26.4. Aspirin 12.27. Sweden GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 12.27.1. Oral 12.27.2. Intravenous 12.27.3. Subcutaneous 12.27.4. Others 12.28. Sweden GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 12.28.1. Corticosteroids 12.28.2. Immunosuppressive Agents 12.28.3. Anticoagulants 12.28.4. Others 12.29. CIS countries GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 12.29.1. Prednisone 12.29.2. Methotrexate 12.29.3. Tocilizumab 12.29.4. Aspirin 12.30. CIS countries GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 12.30.1. Oral 12.30.2. Intravenous 12.30.3. Subcutaneous 12.30.4. Others 12.31. CIS countries GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 12.31.1. Corticosteroids 12.31.2. Immunosuppressive Agents 12.31.3. Anticoagulants 12.31.4. Others 12.32. Rest of Europe GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 12.32.1. Prednisone 12.32.2. Methotrexate 12.32.3. Tocilizumab 12.32.4. Aspirin 12.33. Rest of Europe GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 12.33.1. Oral 12.33.2. Intravenous 12.33.3. Subcutaneous 12.33.4. Others 12.34. Rest of Europe GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 12.34.1. Corticosteroids 12.34.2. Immunosuppressive Agents 12.34.3. Anticoagulants 12.34.4. Others 12.35. Europe GIANT CELL ARTERITIS THERAPEUTICS Market Attractiveness Analysis 12.35.1. By Route of Administration 12.35.2. By Therapeutics 12.35.3. By Mechanism of Action 12.36. PEST Analysis 12.37. Key Trends 12.38. Key Developments 13. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Analysis 13.1. Key Findings 13.2. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Overview 13.3. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Therapeutics 13.4. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 13.4.1. Prednisone 13.4.2. Methotrexate 13.4.3. Tocilizumab 13.4.4. Aspirin 13.5. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Route of Administration 13.6. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 13.6.1. Oral 13.6.2. Intravenous 13.6.3. Subcutaneous 13.6.4. Others 13.7. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Mechanism of Action 13.8. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 13.8.1. Corticosteroids 13.8.2. Immunosuppressive Agents 13.8.3. Anticoagulants 13.8.4. Others 13.9. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Country 13.10. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. ASEAN 13.10.7. Rest of Asia Pacific 13.11. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Analysis, By Country 13.12. China GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 13.12.1. Prednisone 13.12.2. Methotrexate 13.12.3. Tocilizumab 13.12.4. Aspirin 13.13. China GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 13.13.1. Oral 13.13.2. Intravenous 13.13.3. Subcutaneous 13.13.4. Others 13.14. China GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 13.14.1. Corticosteroids 13.14.2. Immunosuppressive Agents 13.14.3. Anticoagulants 13.14.4. Others 13.15. India GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 13.15.1. Prednisone 13.15.2. Methotrexate 13.15.3. Tocilizumab 13.15.4. Aspirin 13.16. India GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 13.16.1. Oral 13.16.2. Intravenous 13.16.3. Subcutaneous 13.16.4. Others 13.17. India GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 13.17.1. Corticosteroids 13.17.2. Immunosuppressive Agents 13.17.3. Anticoagulants 13.17.4. Others 13.18. Japan GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 13.18.1. Prednisone 13.18.2. Methotrexate 13.18.3. Tocilizumab 13.18.4. Aspirin 13.19. Japan GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 13.19.1. Oral 13.19.2. Intravenous 13.19.3. Subcutaneous 13.19.4. Others 13.20. Japan GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 13.20.1. Corticosteroids 13.20.2. Immunosuppressive Agents 13.20.3. Anticoagulants 13.20.4. Others 13.21. South Korea GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 13.21.1. Prednisone 13.21.2. Methotrexate 13.21.3. Tocilizumab 13.21.4. Aspirin 13.22. South Korea GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 13.22.1. Oral 13.22.2. Intravenous 13.22.3. Subcutaneous 13.22.4. Others 13.23. South Korea GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 13.23.1. Corticosteroids 13.23.2. Immunosuppressive Agents 13.23.3. Anticoagulants 13.23.4. Others 13.24. Australia GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 13.24.1. Prednisone 13.24.2. Methotrexate 13.24.3. Tocilizumab 13.24.4. Aspirin 13.25. Australia GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 13.25.1. Oral 13.25.2. Intravenous 13.25.3. Subcutaneous 13.25.4. Others 13.26. Australia GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 13.26.1. Corticosteroids 13.26.2. Immunosuppressive Agents 13.26.3. Anticoagulants 13.26.4. Others 13.27. ASEAN GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 13.27.1. Prednisone 13.27.2. Methotrexate 13.27.3. Tocilizumab 13.27.4. Aspirin 13.28. ASEAN GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 13.28.1. Oral 13.28.2. Intravenous 13.28.3. Subcutaneous 13.28.4. Others 13.29. ASEAN GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 13.29.1. Corticosteroids 13.29.2. Immunosuppressive Agents 13.29.3. Anticoagulants 13.29.4. Others 13.30. Rest of Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 13.30.1. Prednisone 13.30.2. Methotrexate 13.30.3. Tocilizumab 13.30.4. Aspirin 13.31. Rest of Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 13.31.1. Oral 13.31.2. Intravenous 13.31.3. Subcutaneous 13.31.4. Others 13.32. Rest of Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 13.32.1. Corticosteroids 13.32.2. Immunosuppressive Agents 13.32.3. Anticoagulants 13.32.4. Others 13.33. Asia Pacific GIANT CELL ARTERITIS THERAPEUTICS Market Attractiveness Analysis 13.33.1. By Therapeutics 13.33.2. By Route of Administration 13.33.3. By Mechanism of Action 13.34. PEST Analysis 13.35. Key Trends 13.36. Key Developments 14. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Analysis 14.1. Key Findings 14.2. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Overview 14.3. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Therapeutics 14.4. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 14.4.1. Prednisone 14.4.2. Methotrexate 14.4.3. Tocilizumab 14.4.4. Aspirin 14.5. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Route of Administration 14.6. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 14.6.1. Oral 14.6.2. Intravenous 14.6.3. Subcutaneous 14.6.4. Others 14.7. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Mechanism of Action 14.8. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 14.8.1. Corticosteroids 14.8.2. Immunosuppressive Agents 14.8.3. Anticoagulants 14.8.4. Others 14.9. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Country 14.10. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.10.5. Rest of Middle East & Africa 14.11. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Analysis, By Country 14.12. GCC Countries GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 14.12.1. Prednisone 14.12.2. Methotrexate 14.12.3. Tocilizumab 14.12.4. Aspirin 14.13. GCC Countries GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 14.13.1. Oral 14.13.2. Intravenous 14.13.3. Subcutaneous 14.13.4. Others 14.14. GCC Countries GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 14.14.1. Corticosteroids 14.14.2. Immunosuppressive Agents 14.14.3. Anticoagulants 14.14.4. Others 14.15. South Africa GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 14.15.1. Prednisone 14.15.2. Methotrexate 14.15.3. Tocilizumab 14.15.4. Aspirin 14.16. South Africa GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 14.16.1. Oral 14.16.2. Intravenous 14.16.3. Subcutaneous 14.16.4. Others 14.17. South Africa GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 14.17.1. Corticosteroids 14.17.2. Immunosuppressive Agents 14.17.3. Anticoagulants 14.17.4. Others 14.18. Nigeria GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 14.18.1. Prednisone 14.18.2. Methotrexate 14.18.3. Tocilizumab 14.18.4. Aspirin 14.19. Nigeria GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 14.19.1. Oral 14.19.2. Intravenous 14.19.3. Subcutaneous 14.19.4. Others 14.20. Nigeria GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 14.20.1. Corticosteroids 14.20.2. Immunosuppressive Agents 14.20.3. Anticoagulants 14.20.4. Others 14.21. Egypt GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 14.21.1. Prednisone 14.21.2. Methotrexate 14.21.3. Tocilizumab 14.21.4. Aspirin 14.22. Egypt GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 14.22.1. Oral 14.22.2. Intravenous 14.22.3. Subcutaneous 14.22.4. Others 14.23. Egypt GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 14.23.1. Corticosteroids 14.23.2. Immunosuppressive Agents 14.23.3. Anticoagulants 14.23.4. Others 14.24. Rest of Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 14.24.1. Prednisone 14.24.2. Methotrexate 14.24.3. Tocilizumab 14.24.4. Aspirin 14.25. Rest of Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 14.25.1. Oral 14.25.2. Intravenous 14.25.3. Subcutaneous 14.25.4. Others 14.26. Rest of Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 14.26.1. Corticosteroids 14.26.2. Immunosuppressive Agents 14.26.3. Anticoagulants 14.26.4. Others 14.27. Middle East & Africa GIANT CELL ARTERITIS THERAPEUTICS Market Attractiveness Analysis 14.27.1. By Therapeutics 14.27.2. By Route of Administration 14.27.3. By Mechanism of Action 14.28. PEST Analysis 14.29. Key Trends 14.30. Key Developments 15. South America GIANT CELL ARTERITIS THERAPEUTICS Market Analysis 15.1. Key Findings 15.2. South America GIANT CELL ARTERITIS THERAPEUTICS Market Overview 15.3. South America GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Therapeutics 15.4. South America GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 15.4.1. Prednisone 15.4.2. Methotrexate 15.4.3. Tocilizumab 15.4.4. Aspirin 15.5. South America GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Route of Administration 15.6. South America GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 15.6.1. Oral 15.6.2. Intravenous 15.6.3. Subcutaneous 15.6.4. Others 15.7. South America GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Mechanism of Action 15.8. South America GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 15.8.1. Corticosteroids 15.8.2. Immunosuppressive Agents 15.8.3. Anticoagulants 15.8.4. Others 15.9. South America GIANT CELL ARTERITIS THERAPEUTICS Market Value Share Analysis, By Country 15.10. South America GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Country 15.10.1. Brazil 15.10.2. Colombia 15.10.3. Argentina 15.10.4. Rest of South America 15.11. South America GIANT CELL ARTERITIS THERAPEUTICS Market Analysis, By Country 15.12. Brazil GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 15.12.1. Prednisone 15.12.2. Methotrexate 15.12.3. Tocilizumab 15.12.4. Aspirin 15.13. Brazil GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 15.13.1. Oral 15.13.2. Intravenous 15.13.3. Subcutaneous 15.13.4. Others 15.14. Brazil GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 15.14.1. Corticosteroids 15.14.2. Immunosuppressive Agents 15.14.3. Anticoagulants 15.14.4. Others 15.15. Colombia GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 15.15.1. Prednisone 15.15.2. Methotrexate 15.15.3. Tocilizumab 15.15.4. Aspirin 15.16. Colombia GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 15.16.1. Oral 15.16.2. Intravenous 15.16.3. Subcutaneous 15.16.4. Others 15.17. Colombia GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 15.17.1. Corticosteroids 15.17.2. Immunosuppressive Agents 15.17.3. Anticoagulants 15.17.4. Others 15.18. Argentina GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 15.18.1. Prednisone 15.18.2. Methotrexate 15.18.3. Tocilizumab 15.18.4. Aspirin 15.19. Argentina GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 15.19.1. Oral 15.19.2. Intravenous 15.19.3. Subcutaneous 15.19.4. Others 15.20. Argentina GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 15.20.1. Corticosteroids 15.20.2. Immunosuppressive Agents 15.20.3. Anticoagulants 15.20.4. Others 15.21. Rest of South America GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Therapeutics 15.21.1. Prednisone 15.21.2. Methotrexate 15.21.3. Tocilizumab 15.21.4. Aspirin 15.22. Rest of South America GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Route of Administration 15.22.1. Oral 15.22.2. Intravenous 15.22.3. Subcutaneous 15.22.4. Others 15.23. Rest of South America GIANT CELL ARTERITIS THERAPEUTICS Market Forecast, By Mechanism of Action 15.23.1. Corticosteroids 15.23.2. Immunosuppressive Agents 15.23.3. Anticoagulants 15.23.4. Others 15.24. South America GIANT CELL ARTERITIS THERAPEUTICS Market Attractiveness Analysis 15.24.1. By Therapeutics 15.24.2. By Route of Administration 15.24.3. By Mechanism of Action 15.25. PEST Analysis 15.26. Key Trends 15.27. Key Developments 16. Company Profiles 16.1. Market Share Analysis, By Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players By price, presence, market share, Route of Administration, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A By Regions, Investment and Route of Administration 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Sanofi 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Kiniksa Pharmaceuticals, Ltd. 16.3.3. Regeneron 16.3.4. GlaxoSmithKline plc 16.3.5. F. Hoffmann-La Roche Ltd. 16.3.6. Novartis AG 16.3.7. AbbVie, Inc. 16.3.8. Bristol-Myers Squibb Company 16.3.9. Abbott 16.3.10. Johnson & Johnson Services, Inc. 16.3.11. Johns Hopkins Hospital 16.3.12. Fortis Healthcare 16.3.13. American College of Rheumatology 16.3.14. Duke University Health System 16.3.15. Lahey Clinic Foundation 16.3.16. Others

About This Report

Report ID 86445
Category Healthcare
Published Date March 2021
Updated Date Oct 2021
Contact Us